Morningstar

Sarepta Therapeutics Inc SRPT

Stock XNAS Rating as of Oct 2, 2026

News

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire Sep 30, 2026, 8:30:00 PM
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

Business Wire Sep 30, 2026, 12:30:00 PM
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

Business Wire Sep 25, 2026, 12:30:00 PM
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

Business Wire Sep 24, 2026, 12:30:00 PM
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

Business Wire Sep 8, 2026, 1:00:00 PM
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

PR Newswire Sep 5, 2026, 2:00:00 AM
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Business Wire Aug 31, 2026, 8:30:00 PM
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Business Wire Aug 24, 2026, 4:02:00 PM
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Business Wire Aug 5, 2026, 8:05:00 PM
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire Jul 29, 2026, 9:00:00 PM
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

Business Wire Jul 27, 2026, 12:30:00 PM
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

Business Wire Jul 22, 2026, 12:30:00 PM
Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

MarketWatch Nov 4, 2025, 2:49:00 AM
How to make money from tax-loss selling between now and the end of the year

MarketWatch Oct 4, 2025, 11:02:00 AM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.